Mankind Pharma Board Approves Financial Results and Amalgamation Schemes
Mankind Pharma Ltd announced the outcome of its Board Meeting held on October 26, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Additionally, the Board considered and approved two Schemes of Arrangement for amalgamation. Scheme 1 involves the amalgamation of wholly-owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited with Mankind Pharma Limited, with an appointed date of April 01, 2027. Scheme 2 involves the amalgamation of Upakarma Ayurveda Private Limited with Mankind Consumer Products Private Limited. Both schemes are subject to necessary statutory and regulatory approvals.
Key Highlights
- Board approved unaudited standalone and consolidated financial results for Q2 FY27.
- Approved Scheme of Arrangement for amalgamation of two wholly-owned subsidiaries.
- Approved Scheme of Arrangement for amalgamation of a step-down wholly-owned subsidiary.
- Amalgamation schemes are subject to regulatory and shareholder approvals.
- Appointed date for first amalgamation scheme is April 01, 2027.
Price Impact
More from MANKIND